浙江省科技型企业---加速您的多肽研究
首页 >多肽产品 >(Des-Gly¹⁰,Leu⁶,Pro-NHEt⁹)-LHRH、亮丙瑞林EP杂质C:Leuprorelin EP Impurity C

多肽产品

54785-87-4,八肽pGlu-HWSYLLRP-NHEt,Pyr-His-Trp-Ser-Tyr-Leu-Leu-Arg-Pro-NHEt,pGlu-HWSYLLRP-NHEt,杭州专肽生物的产品

(Des-Gly¹⁰,Leu⁶,Pro-NHEt⁹)-LHRH、亮丙瑞林EP杂质C:Leuprorelin EP Impurity C

亮丙瑞林Ph.Eur的杂质C。专着。

编号:200208

CAS号:54785-87-4

单字母:Pyr-HWSYLLRP-NHEt

纠错
  • 编号:200208
    中文名称:(Des-Gly¹⁰,Leu⁶,Pro-NHEt⁹)-LHRH、亮丙瑞林EP杂质C:Leuprorelin EP Impurity C
    英文名: (Des-Gly¹⁰,Leu⁶,Pro-NHEt⁹)-LHRH
    CAS号:54785-87-4
    单字母:Pyr-HWSYLLRP-NHEt
    三字母:Pyr

    焦谷氨酸(Glp、pGlu、Pyr)是一种在蛋白质N端位置发现的蛋白质生成氨基酸。它是由N端谷氨酸残基环化形成内酰胺而产生的。

    -His

    L-组氨酸:histidine。系统命名为(2S)-氨基-3-(4-咪唑基)丙酸。其侧链带有弱碱性的咪唑基,为编码氨基酸。是幼小哺乳动物的必需氨基酸。符号:H,His。

    -Trp

    L-色氨酸:tryptophan[e]。系统命名为(2S)-氨基-3-(3-吲哚基)丙酸。是编码氨基酸,哺乳动物的必需氨基酸。符号:W,Trp。某些抗菌素中含有 D-色氨酸。

    -Ser

    L-丝氨酸:serine。系统命名为(2S)-氨基-3-羟基丙酸。是编码氨基酸。因可从蚕丝中获得而得名。符号:S,Ser。在丝原蛋白及某些抗菌素中含有 D-丝氨酸。

    -Tyr

    L-酪氨酸:tyrosine。系统命名为(2S)-氨基-3-(4-羟基苯基)丙酸。是编码氨基酸。符号:Y,Tyr。

    -Leu

    L-亮氨酸:leucine。系统命名为(2S)-氨基-4-甲基戊酸。是编码氨基酸。是哺乳动物的必需氨基酸。符号:L,Leu。

    -Leu

    L-亮氨酸:leucine。系统命名为(2S)-氨基-4-甲基戊酸。是编码氨基酸。是哺乳动物的必需氨基酸。符号:L,Leu。

    -Arg

    L-精氨酸:arginine。系统命名为(2S)-氨基-5-胍基戊酸。在生理条件下带正电荷,为编码氨基酸。是幼小哺乳动物的必需氨基酸。符号:R,Arg。

    -Pro

    L-脯氨酸:proline。系统命名为吡咯烷-(2S)-羧酸。为亚氨基酸。是编码氨基酸。在肽链中有特殊作用,如易形成顺式的肽键等。符号:P,Pro。

    -NHEt

    C端乙胺基化修饰

    氨基酸个数:8
    分子式:C59H84N16O12
    平均分子量:1209.4
    精确分子量:1208.65
    等电点(PI):-
    pH=7.0时的净电荷数:2.24
    平均亲水性:-1.0857142857143
    疏水性值:-0.54
    消光系数:6990
    来源:人工化学合成,仅限科学研究使用,不得用于人体。
    储存条件:负80℃至负20℃
    标签:促黄体生成激素释放激素(LHRH)    亮丙瑞林系列    垂体和下丘脑激素   

  • Impurity C of the Leuprorelin Ph. Eur. monograph.

    Definition
    Luteinizing hormone-releasing hormone (LHRH), also known as Gonadotropin-Releasing Hormone (GnRH) or Luteinizing Hormone-Releasing Factor (LRF) is a hypothalamic neuropeptide which acts on the pituitary to stimulate the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

    Discovery
    LHRH was first characterized by the groups of two Nobel Laureates Guillemin and Schally in 1977. The hypophysiotropic form of the peptide  is part of a larger family of decapeptides and was the first to be discovered and characterized in mammals. The discovery of multiple LHRHs in mammalian and non-mammalian species across a wide evolutionary taxa [over 20 LHRHs identified to date] has resulted in a nomenclature based on the species each of the LHRHs was first discovered 1.

    Structural Characteristics
    LHRH is translated from the mRNA as a pro-hormone, which is subsequently converted to the mature decapeptide (pGlu-His- Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) in secretory vesicles prior to its release 2. Subsequent to its secretion, LHRH may be further cleaved by soluble peptidases for the purposes of degrading, converting, or transforming 3.

    Mode of Action
    The effects of LHRH are mediated by high-affinity G protein-coupled LHRH-receptor (LHRH-R) on pituitary gonadotropes. In humans and most vertebrates, there are two forms of LHRHs, LHRH-I and LHRH-II that exist in the brain and in peripheral tissues. Furthermore, the processed peptide of LHRH-I, LHRH-(1–5), appears also to have biological activities that are in contrast to its parent activities. Enormous interest has been focused on LHRH-I and LHRH-II and their cognate receptors as targets for designing therapies to treat cancers of the reproductive system. LHRH-I is processed by a zinc metalloendopeptidase EC 3.4.24.15 (EP24.15) that cleaves the hormone at the fifth and sixth bond of the decapeptide (Tyr5-Gly6) to form LHRH-(1–5). Autoregulation of LHRH gene expression can also be mediated by its processed peptide, LHRH-(1–5). LHRH-(1–5) may act through one of the alternative LHRH receptors, such as the LHRH-RII. This is plausible since LHRH-(1–5) share the first 4 amino acids with at least 9 LHRH-I forms. LHRH-(1–5) have contrasting effects from its parent peptide, LHRH-I, could help explain the lack of correlation between the action of LHRH-I analogs that behave as antagonists at the pituitary level but result in agonist-like anti-proliferative effects in many cancers 4, ,5.

    Functions

    As growth modulatory factor: LHRH may act as a growth modulatory factor in tumors of the reproductive system. LHRH and LHRH receptors (LHRH-Rs) are expressed in human melanoma cells and LHRH-Rs are found in greater than 50% of human breast cancers 6.

    Action on ovary: LHRH is released in pulses and triggers the production of gonadotropins, which stimulate the growth and release of eggs by the ovary. This fact has been best illustrated by experiments in which the actions of the decapeptide have been blocked by immunoneutralization or receptor antagonist treatment, which invariably leads to cessation or reduction of gonadotropin secretion, disruption of gonadal function, and infertility. Sterility in mutant, non-LHRH-producing mice and human infertility associated with LHRH insufficiency also provide a clear demonstration of the reproductive consequences of inappropriate or deficient LHRH neurosecretion 6. In the rat, administration of an LHRH antagonist during proestrus results in a rapid and complete inhibition of ovulation, demonstrating the importance of this neuropeptide in reproductive function.

    Hypothalamic anovulation: In women, a disorder called hypothalamic anovulation occurs when the hypothalamus does not produce LHRH, which in turn results in a lack of egg production and release by the ovaries. Similarly, if the LHRH secretion pattern is altered by prolonged stressful situations, a female will show symptoms of dysmenorrhea or amenorrhea, while a male will exhibit alteration of steroidogenesis as well as spermatogenesis.

    Reproductive maturation: Regulation of the synthesis and secretion of hypothalamic LHRH neurons plays a fundamental role in the process of reproductive maturation in both mammalian genders. Indeed, an increase in pulsatile LHRH release is the critical factor for the onset of puberty; hypothalamic LHRH content shows a steady increase during the first three months of life in male rats, and an increase in pulsatile LHRH release occurs at the onset of puberty in female rhesus monkeys.

    References

    1.     Walters K, Wegorzewska IN, Chin YP, Parikh MG, Wu TJ (2008). Luteinizing Hormone-Releasing Hormone I (LHRH-I) and Its Metabolite in Peripheral Tissues. Experimental Biology and Medicine, 233 (2):123-130.

    2.     Wetsel WC, Mellon PL, Weiner RI, Negro-Vilar A (1991). Metabolism of pro-luteinizing hormone-releasing hormone in immortalized hypothalamic neurons. Endocrinology, 129:1584-1595.

    3.     Wu TJ, Mani SK, Glucksman MJ, Roberts JL (2005). Stimulation of luteinizing hormone-releasing hormone (LHRH) gene expression in GT1–7 cells by its metabolite, LHRH-(1–5). Endocrinology, 146:280–286.

    4.     Ramakrishnappa N, Rajamahendran R, Lin Y-M, Leung PCK (2005). GnRH in non-hypothalamic reproductive tissues. Anim Reprod Sci., 88:95-113.

    5.     Swanson TA, Kim SI, Myers M, Pabon A, Philibert KD, Wang M, Glucksman MJ. The role of neuropeptide processing enzymes in endocrine (prostate) cancer: EC 3.4.24.15 (EP24.15). Protein Pept Lett., 11:471-478.

    6.     Bajo AM, Schally AV, Halmos G, Nagy A (2003). Targeted Doxorubicin-containing Luteinizing Hormone-releasing Hormone Analogue AN-152 Inhibits the Growth of Doxorubicin-resistant MX-1 Human Breast Cancers. Clinical Cancer Research, 9: 3742-3748.

  • DOI名称
    10.1002/jms.1416In vivo evaluation and in vitro metabolism of leuprolide in mice--mass spectrometry-based biomarker measurement for efficacy and toxicity下载
    10.1016/j.ygcen.2011.10.013Dopamine control of LH release in the tench (Tinca tinca)下载
    10.1208/ps010307A short term (accelerated release) approach to evaluate peptide release from PLGA depot-formulations下载
    10.1034/j.1399-3011.2002.21006.xCharacterization of the solution conformations of leuprolide acetate下载
    10.1002/jps.10257In vitro transdermal iontophoretic delivery of leuprolide-mechanisms under constant voltage application下载
    10.1016/s0168-3659(03)00366-3Monitoring of peptide acylation inside degrading PLGA microspheres by capillary electrophoresis and MALDI-TOF mass spectrometry下载
    10.1208/pt010101Sustained activity and release of leuprolide acetate from an in situ forming polymeric implant下载
    10.1208/pt060242Development of a dialysis in vitro release method for biodegradable microspheres下载
    10.1208/pt060470A model-dependent approach to correlate accelerated with real-time release from biodegradable microspheres下载
    10.1080/07357900600629591Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma下载
    10.2165/00002512-199101060-00008Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders下载
    10.1002/jps.21415Changes in morphology of in situ forming PLGA implant prepared by different polymer molecular weight and its effect on release behavior下载
    10.1007/s00726-010-0549-8Structural elucidation of Leuprolide and its analogues in solution: insight into their bioactive conformation下载
    10.4155/bio.11.39Bioanalytical determination of unstable endogenous small peptides: RFRP3 and its metabolites in rat blood下载
    10.1002/jps.23029Effect of agitation regimen on the in vitro release of leuprolide from poly(lactic-co-glycolic) acid microparticles下载
    10.1016/j.carbpol.2012.05.028S-protected thiolated chitosan: synthesis and in vitro characterization下载
    10.1186/2008-2231-21-57In-vitro/In-vivo comparison of leuprolide acetate release from an in-situ forming plga system下载
  • 暂时没有数据
  • 暂时没有数据